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Abstract: In recent years, advances in molecular biology and cancer research have led to the 
identification of sensitive and specific biomarkers that associate with various types of cancer. 
However, in vivo cancer detection methods with computed tomography, based on tracing and 
detection of these molecular cancer markers, are unavailable today. This paper demonstrates 
in vivo the feasibility of cancer diagnosis based on molecular markers rather than on   anatomical 
structures, using clinical computed tomography. Anti-epidermal growth factor receptor 
conjugated gold nanoparticles (30 nm) were intravenously injected into nude mice implanted 
with human squamous cell carcinoma head and neck cancer. The results clearly demonstrate 
that a small tumor, which is currently undetectable through anatomical computed tomography, 
is enhanced and becomes clearly visible by the molecularly-targeted gold nanoparticles. It is 
further shown that active tumor targeting is more efficient and specific than passive targeting. 
This noninvasive and nonionizing molecular cancer imaging tool can facilitate early cancer 
detection and can provide researchers with a new technique to investigate in vivo the expression 
and activity of cancer-related biomarkers and molecular processes.
Keywords: functional computed tomography, molecular imaging, gold nanoparticles, 
  biologically targeted in vivo imaging, contrast agents
Background
The last decade has brought about major advances in cancer treatment, including the 
development of highly conformal radiation treatments and robotic and endoscopic 
surgery. These techniques rely on accurate target delineation and visualization of 
tumor targets, and require accuracy on the millimeter scale. Therefore, a key priority 
in cancer research involves the development of highly sensitive and specific imaging 
techniques that could vastly improve treatment capabilities through early detection 
of millimeter-sized tumors.
Computed tomography (CT) is among the most convenient imaging/diagnostic tools 
in hospitals today in terms of availability, efficiency, and cost. Undisputedly, this is 
one of the leading technologies applied in overall cancer management. As a diagnostic 
tool, CT provides valuable anatomical information regarding tumor location, size, and 
spread. However, the sensitivity of CT is limited in the detection of subcentimeter 
lesions and its specificity is relatively low, resulting in ∼15% false positive results 
(noncancerous findings that are interpreted as tumors).1 Therefore, improving current 
CT capabilities is critical to cancer detection. This aim can be achieved by expanding 
the role of CT beyond its present structural imaging capabilities and providing it with 
functional and molecular-based imaging capacities as well.
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The development of contrast agents for molecular 
imaging is an emerging field that integrates knowledge 
in chemistry, engineering, and molecular biology to gain 
information on biological processes and to identify diseases 
based on molecular markers, which appear before their 
  clinical symptoms.2,3
Recently, various types of nanoprobes have been devel-
oped as blood pool CT contrast agents, such as gold nano-
probes and nanotags,4–8 iodine-based emulsions,9 and tantalum 
oxide nanoparticles.10 Blood pool contrast agents are mainly 
valuable for early detection of structural and functional abnor-
malities such as those caused by thrombi and atherosclerosis 
lesions in the peripheral vessels.7 Indeed, these agents have 
demonstrated strong X-ray attenuation that allow sharp blood 
vessel delineation, in addition to their prolonged circulation 
time. Moreover, blood pool contrast agents are also capable of 
cancer detection given the leaky nature of tumor vasculature, 
which allows for nanoparticle penetration and accumulation 
in the tumor.11–13 This passively targeted mechanism is caused 
by the enhanced permeability and retention effect.14,15
Cancer detection with actively targeted CT contrast 
agents takes advantage of the overexpression of specific 
surface receptors on cancer cells and of the ability to create 
nanoparticles that can specifically home to these receptors.16 
An important advantage of the active targeting approach is 
the specificity of the findings; however, since this approach 
is based on the existence and degree of overexpression of 
specific tissue biomarkers, it can be applicable only under 
particular biological conditions. Hainfeld et al recently 
showed that gold nanoparticles (GNPs) can enhance the 
visibility of millimeter-sized human breast tumors in mice 
and that active tumor targeting (with anti-Her2 antibodies) 
is more efficient than passive targeting.17 Chanda et al 
demonstrated enhanced CT attenuation of Bombesin 
functionalized GNPs that selectively targeted cancer receptor 
sites.18 However, in vivo CT cancer detection through 
application of high atomic number contrast agents remains 
challenging due to the large amount of gold that must be 
delivered and accumulated on the tumor in order to induce 
sufficient signal to noise ratio in CT. This key factor – the 
total amount of gold per voxel (three-dimensional pixel) – is 
determined mainly by (1) nanoparticle size and their cellular 
labeling efficiency, and (2) the number of overexpressed 
receptors on the cancer cell’s surface.
In this study, based on substantial prior research that 
investigated the delivery of nanoparticles through the tumor 
vasculature, 30 nm GNPs were utilized in order to achieve a 
large amount of gold per voxel. Previous studies demonstrated 
that 30 nm polyethylene glycol (PEG)ylated GNPs traverse 
the systemic circulation, remain undetected by the mononu-
clear phagocyte system, permeate through transendothelial 
pores in tumor blood vessels, and are able to circulate in the 
blood long enough to reach their target.19–21
The head and neck squamous cell carcinoma (SCC) 
was selected as a model system to study, since such tumors 
express an extremely high level of EGFR.22 In addition, 
a direct correlation exists between the degree of EGFR 
overexpression and tumor aggressiveness.23 The anti-EGFR 
antibody is known to be specific to head and neck SCC 
tumors and it is well demonstrated as nontoxic in therapeu-
tic concentrations in humans.24 In this study, the ability of 
anti-EGFR-targeted GNPs to form a concentrated assembly 
exclusively on the SCC cancer cells in tumor-bearing mice 
was investigated. It is demonstrated that the strong selective 
X-ray attenuation by gold nanoprobes assembly, which is 
distinct from the attenuation of other cell types and tissues, 
transforms the targeted tumor into highly distinct and easy 
to diagnose features in CT imaging. This study also demon-
strates that active tumor targeting was more efficient than 
passive targeting (at specific time points), possibly because 
of its elevated tumor uptake and retention forces.25
Methods
Preparation of particles
As targeted contrast agents, 30 nm GNPs were prepared using 
sodium citrate, according to the methodology described by 
Enüstun and Turkevich.26 Particle size, shape, and uniformity 
were measured using transmission electron microscopy and 
proved to be 30 nm diameter spheres with narrow size dis-
tribution (10%), as shown in Figure 1. A protective layer of 
PEG was absorbed on the surface of the GNPs in order to 
reduce nonspecific interactions and to prolong circulation 
time of the nanoparticles in the blood stream.27 The PEG 
layer consisted of a mixture of thiol-polyethylene-glycol 
(mPEG-SH) (~85%, MW ~5 kDa) and a heterofunctional 
thiol-PEG-acid (SH-PEG-COOH) (~15%, MW ~3.4 kDa) 
(Creative PEGWorks, Winston Salem, NC).
For cancer cell targeting, the heterofunctional PEG was 
covalently conjugated to an anti-EGFR monoclonal antibody 
(Erbitux®, Merck KGaA, Darmstadt, Germany), and as a 
negative control to an anti-rabbit immunoglobulin G (IgG) 
antibody (Jackson ImmunoResearch Laboratories, Inc, West 
Grove, PA), using 1-ethyl-3-(3-(dimethylaminopropyl)-
carbodiimide and N-hydroxysulfosuccinimide (Thermo 
Fisher Scientific, Inc, Rockford, IL).28,29 The antibody-
conjugated GNPs were stable for up to 3 months, confirmed 
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by their maintenance of the same plasmon resonance. The 
coated GNPs were characterized using ultraviolet-visible 
spectroscopy (UV-1650 PC; Shimadzu Corporation, Kyoto, 
Japan) and zeta potential30 (ZetaSizer 3000HS; Malvern 
Instruments, Malvern, UK) (Figure 1).
In vitro cell binding experiment
A431 cells (2.5 × 106) in 5 mL Dulbecco’s modified 
Eagle’s medium containing 5% fetal calf serum, 0.5% 
  penicillin, and 0.5% glutamine were divided into two groups 
for a quantitative cell binding study (each experimental 
group was run in triplicate). The first group was incubated 
with 50 µL of anti-EGFR-coated GNPs (25 mg/mL) for 
30   minutes at 37°C and the second group (negative control) 
was incubated at the exact same conditions with anti-rabbit 
IgG-coated GNPs. After incubation, the medium was washed 
twice with phosphate buffered saline followed by addition 
of 1 mL of aqua regia. After evaporation of the acid, the 
  sediment was dissolved in 5 mL 0.05 M hydrochloride. 
The gold concentrations of the samples were quantified 
by atomic absorption spectroscopy (AA 140; Agilent 
Technologies, Santa Clara, CA).
In vivo experiment
A431 cells (2 × 106) were injected subcutaneously into 
the back flank area of six nude mice of age 10–11 weeks. 
The mice were divided into two groups of three each for 
active (GNPs coated with anti-EGFR antibodies) and   passive 
(GNPs coated with anti-rabbit IgG antibodies) targeting 
  studies. As a control, the two mice groups were scanned 
before GNPs injection.
When the tumor size reached a diameter of 4–5 mm, the 
nude mice received 200 µL (25 mg/mL gold) of immuno-
targeted GNPs by tail vein injection. The mice were scanned 
before injection to determine the CT baseline, as well as every 
hour post injection up to 6 hours. The scans were performed 
using a clinical 64 detector CT scanner (LightSpeed VCT, GE 
Healthcare, Little Chalfont, UK), with scanning parameters 
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Figure 1 Characterization of gold nanoparticles (GNPs). Upper left: transmission electron microscopy image of 30 nm GNPs (scale bar 100 nm). Upper right: zeta potential 
measurements at the various stages of GNP coatings. Bottom: ultraviolet-visible spectroscopy of the bare GNPs, polyethylene glycol (PEG)ylated GNPs, and anti-epidermal 
growth factor receptor (EGFR)-coated GNPs. 
Abbreviations: A.U, abitrary unit; IgG, immunoglobulin G.
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of 80 kVp and 500 mAs. The contrast enhancement was 
quantitatively determined according to the differential con-
trast in CT numbers (in Hounsfield units [HU]), compared to 
that of the same mouse before injection. All CT scans were 
performed under appropriate anesthesia. Up to 7 days post 
intravenous injection, mouse behavior was normal and no 
evidence was observed of toxicity.
Results and discussion
In vitro cell binding experiment
In order to evaluate the specificity of the interaction between 
the antibody-coated GNPs and the A431 SCC cancer cells 
(which highly express EGFR), two types of GNPs were 
introduced to the cells; the first was specifically coated with 
anti-EGFR antibody, whilst the second, which was used as 
a negative control, was coated with a nonspecific antibody 
(anti-rabbit IgG). Atomic absorption spectroscopy measure-
ments quantitatively demonstrated that active tumor targeting 
(anti-EGFR-coated GNPs) was significantly more specific 
than the control experiment (antirabbit IgG-coated GNPs). 
The A431 cells took up 26.3 ± 2.3 µg of targeted GNPs 
(3.9 × 104 GNPs per A431 cell) whilst parallel cells in the 
negative control experiment absorbed only 0.2 ± 0.01 µg of 
GNPs (3.4 × 103 GNPs per cell). The results correlate well 
with previously published studies which report that head 
and neck SCC express from 2 × 104 to 2 × 106 EGFRs per 
cell.31,32
In vivo CT experiments
The ability of CT to detect tumors based on molecularly-
targeted contrast agents was evaluated in mice bearing human 
head and neck tumors derived from the A431 SCC cell line. 
At the first stage of the experiment (0–3 hours), no   significant 
difference was observed between the   accumulation of the 
active and passive targeted particles. From that point on 
(3–6 hours), the accumulation of the actively targeted GNPs 
was steadily elevated, whilst the nontargeted particles were 
gradually cleared from the tumor. Maximal   accumulation 
of the actively targeted particles was achieved 6 hours post 
GNPs injection. At this time point, the CT number of the 
tumor that was specifically targeted by the anti-EGFR-
coated gold nanorods (Figure 2C) was over five times higher 
than the CT number of the same tumor in the same mouse 
before GNPs injection (190 ± 12 HU versus 34 ± 5 HU, 
  respectively) (Figure 2A). This demonstrates that the 
GNPs were   specifically attached to the SCC head and neck 
tumor at a high density, yielding a distinguishable contrast 
enhancement. The results also demonstrate that this small 
tumor (approximately 4–5 mm in diameter), which was 
undetectable without the GNPs contrast agents (Figure 2A), 
Mouse without GNPs
ABC
Tumor
34 ± 5 HU
Tumor
78 ± 15 HU
Tumor
190 ± 12 HU
Mouse with
nontargeted GNPs
Mouse with
targeted GNPs
Figure 2 In vivo X-ray computed tomography (CT) volume-rendered images of (A) mouse before injection of gold nanoparticles (GNPs), (B) mouse 6 hours postinjection 
of nonspecific immunoglobulin G GNPs as a passive targeting experiment, and (C) mouse 6 hours postinjection of anti-epidermal growth factor receptor (EGFR)-coated 
GNPs that specifically targeted the squamous cell carcinoma head and neck tumor. The anti-EGFR-targeted GNPs show clear contrast enhancement of the tumor (C, yellow 
arrow), which was undetectable without the GNPs contrast agents (A, yellow arrow). CT numbers represent the average Hounsfield units (HU) of the whole tumor area. 
All scans were performed using a clinical CT at 80 kVp, 500 mAs, collimation 0.625 × 64 mm and 0.521 pitch size (64 detector CT scanner, LightSpeed VCT; GE Healthcare, 
Little Chalfont, UK).
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was clearly visible and therefore can be easily detected after 
being specifically targeted by GNPs (Figure 2C).
Active and passive targeting mechanisms were com-
pared at a single time point (6 hours post GNPs injection). 
As shown in Figure 2, active tumor targeting (Figure 2C) 
is more efficient and specific than passive targeting 
 ( Figure 2B), possibly because of elevated tumor uptake and 
retention forces. Passive tumor targeting takes advantage 
of the leaky nature of the tumor vasculature, allowing the 
GNPs to reach the tumor; however, GNPs are more rapidly 
cleared from the tumor and accumulate in the kidney, liver, 
and spleen (Figure 2B), according to their well-described 
clearance mechanism.29,33 The active targeting mechanism 
is highly important for CT contrast agents not only because 
of the specificity of the findings, but even more importantly, 
because the large amount of contrast material in the targeted 
site can overcome the inherently low sensitivity of CT to 
contrast agents.
Another important parameter that should be noted is the 
high differential contrasts that were obtained in the above 
experiments. The signal (defined as the CT number of the 
organ post GNPs injection) relative to the background 
(defined as the CT number of the organ before GNPs injec-
tion) in the active study was significantly higher than the 
equivalent value obtained in the passive study. This results 
in poor contrast and low detectability of the passively 
  targeted tumor (Figure 3). The lower accumulation of the 
passively targeted GNPs onto the tumor in comparison to the 
  accumulation obtained in the actively targeted GNPs (78 HU 
versus 190 HU, respectively), yields higher accumulation 
in the kidney (42 HU versus 34 HU, respectively) and liver 
(96 HU versus 63 HU, respectively).
It is important to note that these results were obtained 
using a clinical CT, which has a relatively low resolution 
compared to a micro CT; therefore, they yield high potential 
for clinical application.
Conclusion
In summary, this study demonstrated the feasibility of 
molecular cancer imaging with clinical CT. Targeted GNPs 
are capable of producing contrast enhancement (increased 
X-ray attenuation) so that CT can detect cancer based on 
molecular markers rather than on anatomical structures. 
The strong selective X-ray attenuation by gold nanoprobe 
assembly is distinct from the attenuation of other cell types 
and tissues, and therefore transforms the targeted cancer 
into highly distinct features that are easy to diagnose in 
CT imaging. It was further shown that the CT number of the 
molecularly-targeted tumor is over five times higher than the 
corresponding number of an identical but untargeted tumor 
and that active tumor targeting is more efficient and specific 
than passive targeting. This targeted molecular imaging tool 
is expected to provide a new method to investigate in vivo 
the expression and activity of cancer-related biomarkers, 
to study tumor physiology, and to trace tumors’ molecular 
processes. This primary research will pave the way for a 
further future study to characterize important parameters, 
such as optimal dosing and detection limit, ie, the smallest 
tumor size that can be detected.
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